Osong plant
Stage unconfirmedAntibody plant using perfusion continuous culture.
A biosimilar developer with an Osong plant able to produce more than 2.8 million litres of antibodies a year.
Antibody plant using perfusion continuous culture.
Rituximab and trastuzumab biosimilars in regulatory and clinical stages.
Official role guide
Observed 2026-11-15
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.